Diffuse Large B-Cell Lymphoma (DLBCL) Clinical Trials

9 recruiting

Diffuse Large B-Cell Lymphoma (DLBCL) Trials at a Glance

10 actively recruiting trials for diffuse large b-cell lymphoma (dlbcl) are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Suzhou, Tianjin, and Guangzhou. Lead sponsors running diffuse large b-cell lymphoma (dlbcl) studies include Ou Bai, MD/PHD, Health Institutes of Turkey, and Guangzhou Lupeng Pharmaceutical Company LTD..

Browse diffuse large b-cell lymphoma (dlbcl) trials by phase

Treatments under study

About Diffuse Large B-Cell Lymphoma (DLBCL) Clinical Trials

Looking for clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Diffuse Large B-Cell Lymphoma (DLBCL) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Diffuse Large B-Cell Lymphoma (DLBCL) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 2

Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation

Diffuse Large B-Cell Lymphoma (DLBCL)
The First Affiliated Hospital of Soochow University35 enrolled1 locationNCT07499271
Recruiting
Phase 2Phase 3

NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)

Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Relapsed/Refractory Non-Hodgkin Lymphoma+2 more
Health Institutes of Turkey40 enrolled4 locationsNCT07502118
Recruiting
Phase 2

Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL

Diffuse Large B-Cell Lymphoma (DLBCL)
Ou Bai, MD/PHD50 enrolled1 locationNCT07493148
Recruiting
Phase 3

Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP

Diffuse Large B-Cell Lymphoma (DLBCL)
Ou Bai, MD/PHD200 enrolled1 locationNCT07493109
Recruiting
Phase 2

CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL

Diffuse Large B-Cell Lymphoma (DLBCL)
Tianjin Medical University Cancer Institute and Hospital58 enrolled1 locationNCT07397832
Recruiting
Phase 2

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.150 enrolled41 locationsNCT07189065
Recruiting
Phase 2Phase 3

Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL)
Sun Yat-sen University80 enrolled1 locationNCT07084662
Recruiting
Phase 2

A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP

Diffuse Large B-Cell Lymphoma (DLBCL)
Danielle Wallace40 enrolled1 locationNCT06828991
Recruiting
Phase 1

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

NeoplasmsMultiple Myeloma in RelapseMultiple Myeloma, Refractory+2 more
Technische Universität Dresden16 enrolled1 locationNCT05836896
Recruiting
Phase 2

Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL)
Second Affiliated Hospital, School of Medicine, Zhejiang University48 enrolled1 locationNCT07078500